<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00122031</url>
  </required_header>
  <id_info>
    <org_study_id>BSG-04-006</org_study_id>
    <nct_id>NCT00122031</nct_id>
  </id_info>
  <brief_title>Deep Brain Stimulation for Treatment-Refractory Major Depression</brief_title>
  <official_title>Deep Brain Stimulation for Treatment-Refractory Major Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the use of deep brain stimulation (DBS) to reduce symptom
      severity and enhance the quality of life for patients with treatment-refractory major
      depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite advances in pharmacotherapy and psychotherapy for major depression, a substantial
      number of patients fail to improve significantly even after years of conventional and
      experimental interventions. Bilateral deep brain stimulation (DBS) to the region of the
      anterior capsule/ventral striatum is an adjustable and reversible procedure that may be a
      more effective treatment for patients with major depression. This study will determine the
      effectiveness, safety, and tolerability of DBS in patients with treatment-refractory major
      depression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale (HDRS)</measure>
    <time_frame>analyzed at 12 and 24 month after stimulation onset</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>analyzed at 12 and 24 month after stimulation onset</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>DBS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Deep Brain Stimulation with Medtronic Activa Neurostimulator</intervention_name>
    <description>Deep brain stimulation (DBS) at 130 Hz</description>
    <arm_group_label>DBS</arm_group_label>
    <other_name>Activa Neurostimulator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major depression (MD), severe, unipolar type

          -  German mother tongue

          -  Hamilton Depression Rating Scale (HDRS24) score of &gt; 20

          -  Global Assessment of Function (GAF) score of &lt; 45

          -  At least 4 episodes of MD or chronic episode &gt; 2 years

          -  &gt; 5 years after first episode of MD

          -  Failure to respond to *adequate trials (&gt;5 weeks at the maximum recommended or
             tolerated dose) of primary antidepressants from at least 3 different classes;

               -  adequate trials (&gt;3 weeks at the usually recommended or maximum tolerated dose)
                  of augmentation/combination of a primary antidepressant using at least 2
                  different augmenting/combination agents (lithium, T3, stimulants, neuroleptics,
                  anticonvulsants, buspirone, or a second primary antidepressant); *an adequate
                  trial of electroconvulsive therapy [ECT] (&gt;6 bilateral treatments) and; *an
                  adequate trial of individual psychotherapy (&gt;20 sessions with an experienced
                  psychotherapist).

          -  Able to give written informed consent

          -  No medical comorbidity

          -  Drug free or on stable drug regimen at least 6 weeks before study entry

        Exclusion Criteria:

          -  Current or past nonaffective psychotic disorder

          -  Any current clinically significant neurological disorder or medical illness affecting
             brain function, other than motor tics or Gilles de la Tourette syndrome

          -  Any clinically significant abnormality on preoperative magnetic resonance imaging
             (MRI)

          -  Any surgical contraindications to undergoing DBS

          -  Current or unstably remitted substance abuse (aside from nicotine)

          -  Pregnancy and women of childbearing age not using effective contraception

          -  History of severe personality disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas E Schlaepfer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bonn</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Volker Sturm, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Cologne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy, University of Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Cohen MX, Axmacher N, Lenartz D, Elger CE, Sturm V, Schlaepfer TE. Good vibrations: cross-frequency coupling in the human nucleus accumbens during reward processing. J Cogn Neurosci. 2009 May;21(5):875-89. doi: 10.1162/jocn.2009.21062.</citation>
    <PMID>18702577</PMID>
  </reference>
  <reference>
    <citation>Lieb K, Schlaepfer TE. Deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006 Nov 23;355(21):2256; author reply 2256.</citation>
    <PMID>17124028</PMID>
  </reference>
  <reference>
    <citation>Kosel M, Sturm V, Frick C, Lenartz D, Zeidler G, Brodesser D, Schlaepfer TE. Mood improvement after deep brain stimulation of the internal globus pallidus for tardive dyskinesia in a patient suffering from major depression. J Psychiatr Res. 2007 Nov;41(9):801-3. Epub 2006 Sep 8.</citation>
    <PMID>16962613</PMID>
  </reference>
  <results_reference>
    <citation>Schlaepfer TE, Cohen MX, Frick C, Kosel M, Brodesser D, Axmacher N, Joe AY, Kreft M, Lenartz D, Sturm V. Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology. 2008 Jan;33(2):368-77. Epub 2007 Apr 11.</citation>
    <PMID>17429407</PMID>
  </results_reference>
  <results_reference>
    <citation>Bewernick BH, Hurlemann R, Matusch A, Kayser S, Grubert C, Hadrysiewicz B, Axmacher N, Lemke M, Cooper-Mahkorn D, Cohen MX, Brockmann H, Lenartz D, Sturm V, Schlaepfer TE. Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol Psychiatry. 2010 Jan 15;67(2):110-6. doi: 10.1016/j.biopsych.2009.09.013.</citation>
    <PMID>19914605</PMID>
  </results_reference>
  <results_reference>
    <citation>Bewernick BH, Kayser S, Sturm V, Schlaepfer TE. Long-term effects of nucleus accumbens deep brain stimulation in treatment-resistant depression: evidence for sustained efficacy. Neuropsychopharmacology. 2012 Aug;37(9):1975-85. doi: 10.1038/npp.2012.44. Epub 2012 Apr 4.</citation>
    <PMID>22473055</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2005</study_first_submitted>
  <study_first_submitted_qc>July 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2005</study_first_posted>
  <last_update_submitted>June 13, 2012</last_update_submitted>
  <last_update_submitted_qc>June 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Thomas E. Schlaepfer, MD</investigator_full_name>
    <investigator_title>Professor of Psychiatry and Psychotherapy</investigator_title>
  </responsible_party>
  <keyword>Major Depression</keyword>
  <keyword>Treatment Refractory Major Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

